Positron emission tomography (PET)‐CT with the 68Ga‐labelled prostate specific membrane antigen (PSMA) ligand 11 has emerged as a challenger in the staging of patients with high‐risk PCa with the most recent data from Hofman et al. showing promising results.29 The gene discussed is FOLH1; the disease is posterior cortical atrophy.